Mental health policy and psychotropic drugs

Milbank Quarterly

Volumn 83, Issue 2, 2005, Pages 271-298

  Frank, Richard G ^a,c   Conti, Rena M ^b   Goldman, Howard H ^d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Research Network on Successful Midlife Development   (United States)

Author keywords

Managed behavioral healthcare; Mental health policy; Mental health treatment; Psychotropic drugs

Indexed keywords

PSYCHOTROPIC AGENT;

ADULT; ADVERTIZING; CLASSIFICATION; ECONOMICS; HEALTH CARE AND PUBLIC HEALTH; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; MEDICAID; MENTAL DISEASE; MENTAL HEALTH THERAPIES; ORGANIZATION AND MANAGEMENT; REVIEW; UNITED STATES;

HEALTH CARE AND PUBLIC HEALTH; MENTAL HEALTH THERAPIES;

ADULT; ADVERTISING; HEALTH POLICY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAID; MENTAL DISORDERS; PRIVATE SECTOR; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 22344448455     PISSN: 0887378X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-0009.2005.00347.x     Document Type: Review

References (60)

1. Agency for Health Care Policy and Research (now AHRQ). 1999. Treatment of Depression - Newer Pharmacotherapies. Evidence Report/Technology Assessment, no. 7, publ. no. 99-E014. Rockville, Md.
2. Agency for Health Care Research and Quality (AHRQ), Medical Expenditure Panel Survey (MEPS), Full Year Consolidated Data Files 1996-2004. Available at http://www.meps.ahrq.gov/.
3. Allison, D.B., J.L. Mentore, M. Heo, L.P. Chandler, J.C. Capperlleri, M.C. Infante, and P.J. Weiden. 1999. Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. American Journal of Psychiatry 156(11):1686-96.
4. Anderson, I.M., and B.M. Tomenson. 1994. The Efficacy of Selective Serotonin Reuptake Inhibitors in Depression: A Meta-analysis of Studies against Tricyclic Anti-depressants. Journal of Psychopharmacology 8:238-49.
5. Anderson, I.M., and B.M. Tomenson. 1995. Treatment Discontinuation with Selective Serotonin Reuptake Inhibitors Compared with Tricyclic Anti-depressants: A Meta-analysis. British Medical Journal 310:1433-8.
6. Berndt, E.R. 2002. Trends and Drivers of Expenditures on Psychotropic Drugs in the U.S. Paper presented at the NIMH Workshop on Pharmacoeconomics, Washington, May 2003.
7. Berndt, E.R., S.H. Busch, and R.G. Frank. 2000. Price Indexes for Acute Care Treatment of Depression. In Medical Care Productivity, edited by D. Cutler and E.R. Berndt, 463-505. Chicago: University of Chicago Press.
8. Berndt, E.R., R.G. Frank, and T.G. McGuire. 1997. Alternative Insurance Arrangements and the Treatment of Depression: What Are the Facts? American Journal of Managed Care 3(2):135-43.
9. Busch, A.B., R.G. Frank, and A. Lehman. 2004. The Effect of a Managed Behavioral Health Care Carve-out on Quality of Care for Medicaid Patients Diagnosed as Having Schizophrenia. Archives of General Psychiatry 61:442-8.
10. Busch, S.H. 2002. Specialty Health Care, Treatment Patterns, and Quality: The Impact of a Mental Health Carve-out on Care for Depression. Health Services Research 37(6):1583-1601.
11. Center for Medicare and Medicaid Services. 2004. National Health Expenditures Table. Available at http://www.cms.hhs.gov/statistics/nhe/ historical/t10.asp (accessed August 23, 2004).
12. Chakos, M., J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman. 2001. Effectiveness of Second-Generation Antipsychotics in Patients with Treatment-Resistant Schizophrenia: A Review and Meta-analysis of Randomized Trial. American Journal of Psychiatry 158:518-26.
13. Coffey, R.M., T. Mark, E. King, H. Harwood, D. McKusick, J. Genurardi, J. Dilonardo, and J. Buck. 2000. National Estimates of Expenditures for Mental Health and Substance Abuse Treatment. Rockville, Md.: U.S. Department of Health and Human Services, July.
14. Congressional Budget Office. 2002. Issues in Designing a Medicare Prescription Drug Benefit. Washington, D.C.: October.
15. Croghan, T.W., C.A. Melfi, W.E. Crown, and A. Chawla. 1998. Cost Effectiveness of Anti-depressant Medications. Journal of Mental Health Policy and Economics 1:109-17.
16. Donohue, J., E.R. Berndt, M. Rosenthal, A. Epstein, and R.G. Frank. 2004. Effects of Pharmaceutical Promotion on Adherence to Guideline Treatment of Depression. Medical Care 42(12):1176-85.
17. Duggan, M. 2004. Do New Prescription Drugs Pay for Themselves? The Case of Second-Generation Antipsychotics. Journal of Health Economics 24(1):1-31.
18. Express Scripts. 2001. Drug Trend Report: Trends in Expenditures. Available at http://www.ExpressScripts.com (accessed December 12, 2002).
19. Finkelstein, S.N., E.R. Berndt, and P.E. Greenberg. 1996. Improvement in Subjective Work Performance after Treatment of Chronic Depression: Some Preliminary Results. Psychopharmacology Bulletin 32:34-40.
20. Frank, R.G., E.R. Berndt, J. Donohue, A.M. Epstein, and M.B. Rosenthal. 2002. Trends in Direct-to-Consumer Advertising of Prescription Drugs. A report prepared for the Kaiser Family Foundation, February. Available at http://www.kff.org/rxdrugs/3162-index.cfm (accessed December 20, 2002).
21. Frank, R.G., and S. Glied. 2005. Better But Not Well. Draft monograph, July.
22. Gluck, M.E., and K.W. Hanson. 2001. Medicare Chart Book. Washington, D.C.: Henry Kaiser Family Foundation, fall.
23. Holmer, A. 2002. Direct-to-Consumer Advertising - Strengthening Our Health Care System. New England Journal of Medicine 346(7):526-8.
24. IMS Health. 2005. IMS Report 11.5% Dollar Growth in '03 US Prescription Sales. Available at http://imshealth.com/ims/portal/front/articleC/0,2777, 6599_41382706_44771558,00.html (accessed March 3, 2005).
25. Kaiser Family Foundation. 2001a. Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey and Selected Case Study Highlights, October. Available at http://www.kff.orgcontent/2002/20020213/4003a.pdf (accessed December 18, 2002).
26. Kaiser Family Foundation. 2001b. Prescription Drug Trends: An Update, November. Available at http://www.kff.org/content/2001/3112/RxChartbook.pdf (accessed August 26, 2003).
27. Kaiser Family Foundation. 2004a. Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey, 2003. Available at http://kff.org/medicaid/4164.cfm.
28. Kaiser Family Foundation. 2004b. Medicaid Prescription Drug Spending and Use. Available at http://kff.org/medicaid/7111a.cfm.
29. Kaiser Family Foundation. 2004c. Employer Health Benefits 2004. Annual Survey. Available at http://kff.org/insurance/7148/index.cfm.
30. Katon, W., M. von Korff, E. Lin, J. Unutzer, T. Bush, and J. Ormel. 1992. Adequacy and Duration of Antidepressant Treatment in Primary Care. Medical Care 30:67-76.
31. Kessler, R.C., P. Berglund, O. Demler, R. Jin, D. Kortez, K.R. Merikangas, A.J. Rush, E.E. Walters, and P.S. Wang. 2003. The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289(23):3095-105.
32. Kowalczyk, L. 2002. State Seeks Psychiatric Drug Cuts. Boston Globe, July 12, 1.
33. Lehman, A.F., D.S. Steinwachs, and the Survey Investigators of the PORT Project. 1998. Patterns of Usual Care for Schizophrenia: Initial Results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophrenia Bulletin 24(1):11-20.
34. Le Pen, C., V. Ravily, J.N. Beuzen, and F. Meurgey. 1994. The Cost of Treatment Dropout in Depression: A Cost Benefit Analysis of Fluoxetine vs. Tricyclics. Journal of Affective Disorders 31(1):1-18.
35. Ling, D., R.G. Frank, and E.R. Berndt. 2002. Behavioral Health Carveout Implementation and Diffusion of New Psychotropic Medications in the Medicaid Population. Unpublished manuscript, Harvard University, December.
36. Lund, B.C., P.J. Perry, and J.M. Brooks. 2001. Clozapine Use in Patients with Schizophrenia and the Risk of Diabetes, Hyperlipidemia, and Hypertension. Archives of General Psychiatry 58(12):1172-6.
37. Mark, T., R. Coffey, R. Vandivort-Warren, H. Harwood, E. King. 2005. U.S. Spending for Mental and Substance Abuse Treatment, 1991-2001. Health Affairs (web exclusive). W5: 133-42. March 29, 2005.
38. Mintz, J., L.I. Mintz, M.J. Arruda, and S.S. Hwang. 1992. Treatments of Depression and the Functional Capacity to Work. Archives of General Psychiatry 49:761-8.
39. Montgomery, S.A., J. Henry, G. MacDonald, T. Dinan, M. Laden, I. Hindmarch, A. Clare, and D. Nutt. 1994. Selective Serotonin Reuptake Inhibitors: A Meta Analysis of Discontinuation Rates. Internal Clinical Pharmacology 9:47-53.
40. Newcomer, J.W., D.W. Haupt, R. Fucetola, A.K. Melson, J.A. Schweiger, B.P. Cooper, and G. Selke. 2002. Abnormalities in Glucose Regulation during Antipsychotic Treatment of Schizophrenia. Archives of General Psychiatry 59(4):337-45.
41. NICHM Foundation. 2002. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. Washington, D.C.: May 6.
42. Novartis. 2000. Novartis Pharmacy Benefit Report: 2000 Facts & Figures. Totowa, N.J.: Enron.
43. Pauly, M.V., and Y. Zeng. 2004. Adverse Selection and Challenges to Stand Alone Prescription Drug Insurance. In Frontiers in Health Policy Research, vol. 7, edited by D. Cutler and A.M. Garber, 55-74. Cambridge, Mass.: MIT Press.
44. Prevention Magazine. 2002/3. Consumer Reaction to DTC Advertising of Prescription Medicines. Sixth Annual Survey.
45. Ritter, G., C. Thomas, and S.S. Wallack. 2001. Greater Use of Generics: A Prescription for Drug Cost Savings. Unpublished manuscript, Brandeis University, August.
46. Rosenheck, R.A., J. Cramer, W. Xu, J. Thomas, W. Henderson, L.K. Frisman, C. Fye, and D. Charney. 1997. A Comparison of Clozapine and Haloperidol in the Treatment of Hospitalized Patients with Refractory Schizophrenia. New England Journal of Medicine 337:809-15.
47. Rosenthal, M.B. 1999. Risk Sharing in Managed Behavioral Health Care. Health Affairs 16(5):204-13.
48. Rosenthal, M.B., E.R. Berndt, J.M. Donohue, R.G. Frank, and A.M. Epstein. 2002. Promotion of Prescription Drugs to Consumers. New England Journal of Medicine 346(7):498-505.
49. Scott-Morton, F. 1997. The Strategic Response by Pharmaceutical Firms to the Medicaid Most Favored Customer Rules. RAND Journal of Economics 28(2):269-90.
50. Simon, G., M. von Korff, E.H. Wagner, and W. Barlow. 1993. Patterns of Anti-depressant Use in Community Practice. General Hospital Psychiatry 15:399-408.
51. Song, F., N. Freemantle, T.A. Sheldon, A. House, P. Watson, A. Long, and J. Mason. 1993. Selective Serotonin Reuptake Inhibitors: Meta-analysis of Efficacy and Acceptability. British Medical Journal 306:683-7.
52. Substance Abuse and Mental Health Services Administration (SAMHSA). 2000. Medicare, Medicaid and Managed Care Analyses Project. Contract report 280-95-0011, December.
53. U.S. Congress, Office of Technology Assessment. 1993. Pharmaceutical R&D: Costs, Risks and Rewards. Washington, D.C.: U.S. Government Printing Office.
54. U.S. Department of Health and Human Services (USDHHS). 1999. Mental Health: A Report of the Surgeon General. Rockville, Md.
55. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 2001. 2000 Report to the Nation: Improving Public Health through Human Drugs. Rockville, Md.
56. Wells, K.B., C. Sherbourne, M. Schoenbaum, N. Duan, L. Meredith, J. Unutzer, J. Miranda, M.F. Carney, and L.V. Rubenstein. 2000. Impact of Disseminating Quality Improvement Programs for Depression in Managed Primary Care. Journal of the American Medical Association 283(2):212-20.
57. William M. Mercer, Inc. 2001. Prescription Drug Coverage and Formulary Use in California: Different Approaches and Emerging Trends. Oakland: California HealthCare Foundation, May.
58. Wirshing, D.A., W.C. Wirshing, L. Kysar, M.A. Berisford, D. Goldstein, J. Pashdag, J. Mintz, and S.R. Marder. 1999. Novel Antipsychotics: Comparison of Weight Gain Liabilities. Journal of Clinical Psychiatry 60(6):358-63.
59. Wolfe, S. 2002. Direct to Consumer Advertising: Education or Emotion Promotion? New England Journal of Medicine 346(7):524-6.
60. Wrobel, M.V., J. Doshi, B.C. Stuart, and B. Briesacher. 2003/4. Predictability of Prescription Drug Expenditures for Medicare Beneficiaries. Health Care Financing Review 25(2):37-46.